A Blend of Molecular Pathology, Nuclear Medicine and Clinical Pharmacology

Date: 28.-30. September 2016

Location: Van-Swieten Saal, Medical University Vienna, Austria

Organizing Committee:

Johannes Czernin (UCLA - Los Angeles, USA), Elisabeth de Vries (UMCG - Groningen, Netherlands),

Thomas Beyer, Gerda Egger, Marcus Hacker, Lukas Kenner, Oliver Langer, Markus Mitterhauser, Sharokh Shariat, Wolfgang Wadsak, Markus Zeitlinger (all MUW - Vienna, Austria)

Objective. Modern patient care depends on access to state-of-the-art diagnostics including imaging, pathology and data analysis methods. These fields, while being in active pursuit by several groups, cannot be regarded independently anymore. Today, a number of novel and effective pharmaceuticals for therapeutic interventions are available but treatment response is limited due to insufficient a priori patient selection.

If we want to expand on our understanding of disease mechanisms, shortcut target identification and progress in the assessment of subsequent, novel therapeutic approaches, wider collaborative efforts across existing boundaries of medical disciplines and applied sciences are needed. These efforts must not stop at pointing to selected targets and therapies but support going the last mile to turn effective disease management into cost-effective patient management.

This congress intends to provide a forum to open-minded experts both from academia and industry in the field of molecular pathology, nuclear medicine, clinical pharmacology and beyond who share this vision and like to engage in advancing effective and individualized treatments based on novel and validated diagnostic approaches.

The "Donau Symposium" will be accredited with 14 DFP points. Final approval from the Austrian Medical Chamber is pending.


General Information:


Registration Fees

	until August 31, 2016	on site
Full registration	€ 280	€ 320
Trainees	€ 150	€ 190
Technologists, students	€ 150	€ 190
Single - day ticket		€ 180

Secretariat and registration desk opening hours

Thursday, September 29, 2016: 07:45 – 18:00 Friday, September 30, 2016: 07:45 – 18:00





28. – 30. September 2016 Van-Swieten Saal, Medical University Vienna, Austria

www.applied-diagnostics.eu



DONAU SYMPOSIUM

APPLIED DIAGNOSTICS FOR EFFECTIVE CANCER TREATMENT:



"A Blend of Molecular Pathology, Nuclear Medicine and Clinical Pharmacology" 28.-30. September 2016, Van-Swieten Saal, Medical University Vienna, Austria

PRELIMINARY PROGRAMME Wednesday			08:30-10:30	Applying Diagnostics to Prostate Cancel Chairs: Markus Mitterhauser + tbd		
18:00-19:30	Welcome and Keynote Lecture Chairs: Lukas Kenner + tbd			From man to mice and back: Why model systems matter in pathology! Radiopharmaceuticals for Theranostics in Prostate Cancer	Lukas Kenner (Vienna) John Babich (New York)	
	Welcome:	Markus Müller (Rektor MUW)		Tumor Detection and In-Vivo Tissue Charac	cterization	
	Keynote Lecture: Signaling pathways and inflammation in	N: 1 1/4 : (0 B:)		using PET/MRI Industry Slot	Markus Hartenbach (Vienna) (tbd)	
	the pathogenesis of cancer	Michael Karin (San Diego)	10:30-11:30	Coffee		
19:30-open	Welcome Reception (Van Swieten Saal & Fo	yer)	11:30-13:30	Predicting Response to Targeted Therap Chairs: Christoph Zielinski + tbd	y – Clinical Trials	
Thursday	"Basic Track"			Individualized Treatment of Solid Tumors:		
08:30-10:30	Advanced Concepts in Molecular Path	ology		The EXACT-Trial Molecular Imaging for Drug Development	Gerald Prager (Vienna) Elisabeth De Vries (Groningen)	
	Chairs: Gerda Egger + tbd			Imaging Target Expression and Inhibition: F	Predictive	
	Proteomics Tumor Heterogeneity and Genomics Ko	Matthias Mann (Martinsried)		and Pharmakodynamic Biomarkers	Johannes Czernin (Los Angeles)	
	Epigenomics	Peter Jones (Los Angeles)		Industry Slot	(tbd)	
	Industry Slot	(tbd)	13:30-15:00	Late Austrian Lunch		
10:30-11:30	Coffee		15:00-17:00	5:00-17:00 Novel Tools – Target Definition Chairs: Markus Zeitlinger + tbd		
11:30-13:30				Liquid Biopsies	Michael Spaigher (Croz)	
	Chairs: Marcus Hacker + tbd			Tumor Immunology "Stat3 Suppresses ada	Michael Speicher (Graz) ptive	
	Next Generation of Nuclear Imaging Prot Cancer Diagnosis and Therapy	oes for Jason Lewis (New York)		immunity during tumor initiation"	Florian Greten (Frankfurt/Main)	
	PET with Radiolabeled Anticancer Drugs			Nuclear Imaging Omics Industry Slot	Bernd Pichler (Tübingen) (tbd)	
	Therapy Response In-vivo Target Quantification	Harry Hendrikse (Amsterdam) Adrian Lammertsma (Amsterdam)	17:00-17:30	Summary and Closing Remarks	Megan Lim (Philadelphia)	
	Industry Slot	(tbd)	18:30-19:30	Farewell		
13:30-15:00	Lunch					
15:00-17:00	Advanced Concepts in Clinical Pharm Chairs: Oliver Langer + tbd Role of Transporters in Anticancer Drug Drug-Drug Interactions and Pharmacoge Use of PET Microdosing in Anticancer Drug Development	Disposition: netics Ingolf Cascorbi (Kiel) Mats Bergström (Uppsala)	7			







Industry Slot

Approaches to Overcome the Blood-Brain Barrier to Improve

Brain Delivery of Anticancer Drugs

(tbd)

Olaf van Tellingen (Amsterdam)